Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New ...

IBB ETF analysis: hold rating as biotech consolidates near highs. Fair 19x P/E, low EPS growth and weak seasonality shape ...

Learn how LABD delivers -3x daily biotech exposure, why it’s down 99.98% since inception, and when it fits short-term trades.

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 ...

Stay updated on biotech layoffs in 2026! Each week, we track and analyze industry layoffs, their causes, and their impact.

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

At some point in your research career, you may find yourself transitioning from academia to industry or vice versa. To best set yourself up for success, adapt your approach to the specific scientific ...